Abstract: The invention is directed to a compound for use in the prophylaxis and/or treatment of leukemia and/or the development of leukemia, a pharmaceutical composition for the prophylaxis and/or treatment of leukemia and/or the development of leukemia, comprising said compound, a method for the prophylaxis and/or treatment of leukemia and/or the development of leukemia in a living being, a single guide RNA (sgRNA) molecule which can be used in the method according to the invention.

Abstract: The present invention provides a novel bispecific anti-CD28 antibody format which is bivalent and comprises two CD28 binding sites, and at least one target binding site. The bispecific anti CD28 antibody of the invention is surprisingly advantageous due to its costimulatory activity which is strictly target cell restricted. The bispecific CD28 antibody of the invention is provided for use in the treatment of diseases either alone or in combination with a further bispecific antibody inducing a CD3/T cell receptor signal.

Abstract: The present invention relates to a protein having G-CSF-like activity comprising a) one or two polypeptide chains; b) a bundle of four ?-helices; and c) two or three amino acid linkers that connect contiguous bundle-forming ?-helices that are located on the same polypeptide chain, wherein each amino acid linker has a length between 2 and 20 amino acids. The invention also provides for a polynucleotide and a vector encoding the protein of the invention, host cells comprising said polynucleotide, a method for producing the protein of the invention and a pharmaceutical composition comprising the protein of the invention. The invention further relates to uses of the proteins of the invention as a research reagent and the use of the protein and/or pharmaceutical composition comprising the same as a medicament, e.g., for use in increasing stem cell production, for use in inducing hematopoiesis and/or for use in mobilizing hematopoietic stem cells.

Abstract: The present invention relates to an apparatus for the treatment of an epilepsy-associated disorder in a living being and to a method for the treatment of an epilepsy-associated disorder in a living being.

Abstract: The present invention provides a novel PSMA binding antibody termed 10B3 and pharmaceutical and diagnostic uses of the antibody 10B3. The PSMA antibody 10B3 does not cross-compete with the state of the art PMSA binding antibody J591 and has a reduced induction of antigen shift compared to J591 and a unique reactivity with squamous cell carcinoma (SCC) cells of different origin.

Abstract: Computer-implemented method for transferring style features from at least one source image to a target image, comprising the steps of generating a result image, based on the source and the target image, wherein one or more spatially-variant features of the result image correspond to one or more spatially variant features of the target image; and wherein a texture of the result image corresponds to a texture of the source image; and outputting the result image, and a corresponding device. According to the invention, the texture corresponds to a summary statistic of spatially variant features of the source image.

Abstract: The present invention relates to myeloid-derived suppressor cells (MDSC) and exosomes derived therefrom (MDSC exo) and application thereof.

Abstract: The invention relates to novel infective agents, the use thereof for the production of a pharmaceutical composition for the treatment and prophylaxes of a disease, preferably an infectious disease, a pharmaceutical composition comprising said compound, and to methods of producing said compounds. The invention further relates to a new probiotic configured for preventing or reducing the colonization by a pathogenic microorganism of an organ of a living being.

Abstract: The present invention relates to novel inhibitors of the shikimate pathway (shikimic acid pathway), pharmaceutical compositions comprising these novel inhibitors, methods for the production of the inhibitors and their use as antibiotics and herbicides.

Abstract: The present invention is in the field of the cultivation of biological cells and tissues with organ-like function on a microphysiological scale and provides a method for the microphysiological co-cultivation of 3D organoid tissue and at least one 2D cell layer.

Abstract: The present invention relates to the use of EZH2 inhibitors for the treatment of psoriasis, a pharmaceutical composition for the treatment of psoriasis comprising said EZH2 inhibitors, a method for the preparation of said pharmaceutical composition, a method for the therapeutic treatment of a living being against psoriasis, a method for the screening of active agents against psoriasis, and the use in vitro of a EZH2 inhibitor for the suppression of the cellular I?B? expression.

Abstract: The present invention relates to the use of CDK4/6 inhibitors for the treatment of psoriasis, a pharmaceutical composition for the treatment of psoriasis comprising said CDK4/6 inhibitors, a method for the preparation of said pharmaceutical composition, a method for the therapeutic treatment of a living being against psoriasis, a method for the screening of active agents against psoriasis, and the use in vitro of a CDK4/6 inhibitor for the suppression of the cellular I?B? expression.

Abstract: The invention relates to a polyribonucleotide, a cosmetic and pharmaceutical compound that has the polyribonucleotide and a medicinal product that has the polyribonucleotide and the compound.

Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.

Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.

Abstract: A method is used for determining a status of an encapsulation and/or a passivation layer of the encapsulation. The encapsulation forms a multi-layer system from multiple passivation layers arranged on top of one another and electrically contacted intermediate layers arranged between the passivation layers. The multi-layer system protects an implant surrounded by the encapsulation. In the method, an electrical measurement is carried out between a reference potential and at least one electrically contacted intermediate layer, and at least one current flowing between the reference potential and the at least one electrically contacted intermediate layer is detected. The at least one detected current is compared with at least one pre-determined threshold value. If the detected current falls below or exceeds the at least one threshold value, this indicates a functional state of a passivation layer adjacent to the at least one electrically contacted intermediate layer.

Abstract: The present invention relates to a method for determining in a subject's biological sample the relative proportions of papillary renal cell carcinoma (pRCC), clear cell renal cell carcinoma (ccRCC), and chromophobe renal cell carcinoma (chRCC), an array comprising capture molecules capable of specifically binding to RCC signature genes or coding sequences thereof or products encoded thereby, and the use of RCC signature genes for classifying a subject into a renal cell carcinoma (RCC) risk group and/or for determining in a subject's biological sample the relative proportions of pRCC, ccRCC, and chRCC.

Abstract: A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene.

Abstract: A system or method for motor rehabilitation of a paretic limb including: a first plurality of sensors for registering brain neurosignals; a body-actuator; a hybrid brain machine interface for decoding brain neurosignals into movements of the body-actuator; a second plurality of EMG sensors couplable to the paretic limb for registering its EMG activity; a device for providing the patient with instructions relative to a series of exercises and/or tasks to be carried out with the paretic limb; wherein upon carrying out a series of training sessions, each session comprising at least a set of such instructions, the hybrid brain machine interface is configured to switch between controlling the movements of the body-actuator based on the decoded brain neurosignals and a hybrid control of the movements of the body-actuator, when a significant level of decodable EMG activity has been registered, the hybrid control being an EMG-gated brain control.

Abstract: The present invention relates to substances for the prophylaxis and treatment of a neurodegenerative disease which is not based on a protein-folding disorder. It further relates to substances for the stabilization of photoreceptors.